Granisol
Chemotherapy, Operative Surgery, Nausea + 1 more
Treatment
3 FDA approvals
20 Active Studies for Granisol
Treatment for
Chemotherapy
What is Granisol
Granisetron
The Generic name of this drug
Treatment Summary
Ondansetron is a medication used to prevent nausea and vomiting caused by chemotherapy. It works by blocking serotonin receptors in the body, helping to reduce the feeling of nausea.
Kytril
is the brand name
Granisol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Kytril
Granisetron
1993
63
Approved as Treatment by the FDA
Granisetron, also known as Kytril, is approved by the FDA for 3 uses such as Nausea and vomiting and Nausea .
Nausea and vomiting
Nausea
Chemotherapy
Effectiveness
How Granisol Affects Patients
Granisetron is a drug that blocks serotonin type 3 (5-HT<sub>3</sub>) receptors. It does not have any effect on other serotonin receptors, or on other types of receptors. In studies, it has not impacted blood pressure, heart rate, or ECG readings. This drug is similar to ondansetron, which also blocks 5-HT<sub>3</sub> receptors. When certain drugs are taken, they release serotonin from cells in the small intestine. This serotonin then stimulates nerve receptors in the brain, which can cause nausea and vomiting. Granisetron works by blocking these
How Granisol works in the body
Granisetron stops the vomiting center in your brain from being stimulated. It does this by blocking certain receptors that are found in the vomiting center and in your gastrointestinal tract. This stops signals from your body to the vomiting center that would normally cause you to vomit.
When to interrupt dosage
The recommended dosage of Granisol is contingent upon the diagnosed condition, such as Nausea, Radiation Therapy and Operative Surgery. The amount of dosage is contingent upon the technique of administration (e.g. Solution - Oral or Injection, solution) as recorded in the following table.
Condition
Dosage
Administration
Operative Surgery
, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL
, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Transdermal, Patch - Transdermal, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection - Subcutaneous, Solution - Oral, Liquid - Intravenous, Liquid, Patch, Subcutaneous
Radiation Therapy
, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL
, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Transdermal, Patch - Transdermal, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection - Subcutaneous, Solution - Oral, Liquid - Intravenous, Liquid, Patch, Subcutaneous
Chemotherapy
, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL
, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Transdermal, Patch - Transdermal, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection - Subcutaneous, Solution - Oral, Liquid - Intravenous, Liquid, Patch, Subcutaneous
Nausea
, 1.0 mg/mL, 0.1 mg/mL, 1.0 mg, 0.31 mg/hour, 4.0 mg/mL, 100.0 mg/mL, 1.12 mg/mL, 0.2 mg/mL
, Intravenous, Injection - Intravenous, Injection, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Transdermal, Patch - Transdermal, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection - Subcutaneous, Solution - Oral, Liquid - Intravenous, Liquid, Patch, Subcutaneous
Warnings
There are 20 known major drug interactions with Granisol.
Common Granisol Drug Interactions
Drug Name
Risk Level
Description
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Granisetron is combined with Anagrelide.
Apomorphine
Major
The risk or severity of hypotension can be increased when Granisetron is combined with Apomorphine.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Granisetron is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Granisetron is combined with Artemether.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Granisetron is combined with Asenapine.
Granisol Toxicity & Overdose Risk
The lowest toxic dose of the drug in rats has been found to be greater than 2000mg/kg when taken orally.
Granisol Novel Uses: Which Conditions Have a Clinical Trial Featuring Granisol?
85 active clinical trials are currently underway to ascertain the efficacy of Granisol in alleviating Nausea, Operative Surgery and Radiation Therapy.
Condition
Clinical Trials
Trial Phases
Operative Surgery
68 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2
Radiation Therapy
8 Actively Recruiting
Not Applicable, Phase 1, Phase 3, Phase 2
Nausea
0 Actively Recruiting
Chemotherapy
5 Actively Recruiting
Phase 1, Phase 3, Not Applicable, Phase 2
Patient Q&A Section about granisol
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.